Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Neuroendocrine tumours, drawn from the whole corpus: 60 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Neuroendocrine carcinoma (high grade) behaves like SCLC.
Sequencing of PRRT vs targeted therapy.
Sequencing is unproven: no randomised trial orders SSA, PRRT, everolimus, cabozantinib and chemotherapy.
Also on OnCo: Find a trial · Expert centres.
SSTR-negative, FDG-avid and high-grade disease has few options; neuroendocrine carcinoma outcomes remain poor.
Therapy-related MDS/AML (~2-3%) and renal toxicity after PRRT; long-term data on retreatment are thin.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Overall survival benefits are hard to demonstrate because patients live for years and cross over.
Isotope supply (177Lu, 212Pb, 225Ac) and nuclear-medicine capacity limit access outside major centres.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Chromogranin A is an unreliable marker; better blood tests (NETest, ctDNA) are not validated for decisions.
Rare syndromic and paediatric NETs lack trials; hereditary carriers need lifelong surveillance protocols.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 32 changes by month →When this page itself was last checked or edited.
Histology with Ki-67 grading; 68Ga/64Cu-DOTATATE PET/CT ± FDG PET; triple-phase CT or MRI of the liver; chromogranin A and syndrome-specific hormones; germline testing for pancreatic NETs and paragangliomas. (NCCN Neuroendocrine and Adrenal Tumors)
A milestone in how this cancer is treated.
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
ORR 54.
PFS 23.